Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides
- 1 May 2004
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 22 (3) , 188-192
- https://doi.org/10.1016/j.urolonc.2004.01.010
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cisplatin Biochemical Mechanism of Action: From Cytotoxicity to Induction of Cell Death Through Interconnections Between Apoptotic and Necrotic PathwaysCurrent Medicinal Chemistry, 2003
- Antisense Oligonucleotide Therapy in UrologyJournal of Urology, 2002
- Antisense Bcl2 oligonucleotide in cisplatin‐resistant bladder cancer cell linesBJU International, 2002
- THE EFFECT OF ANTISENSE BCL-2 OLIGONUCLEOTIDES ON BCL-2 PROTEIN EXPRESSION AND APOPTOSIS IN HUMAN BLADDER TRANSITIONAL CELL CARCINOMAJournal of Urology, 2001
- CHEMOSENSITIZATION OF BLADDER CARCINOMA CELLS BY BCL-xL ANTISENSE OLIGONUCLEOTIDESJournal of Urology, 2001
- MOLECULAR TARGETS FOR THE THERAPEUTIC MANIPULATION OF APOPTOSIS IN BLADDER CANCERJournal of Urology, 2001
- Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transferOncogene, 1998
- Programmed cell death and radioresistanceCancer and Metastasis Reviews, 1996
- Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell lineBlood, 1993
- Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.Proceedings of the National Academy of Sciences, 1986